&nbsp;

Intent: Palliative

Drugs Used:

riTUXimab (Unfunded),

lenalidomide (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Regimen

LENV+PEMB

Cancer Type:

Genitourinary,

Renal cell / Kidney

Intent: Palliative

Funding:

Exceptional Access Program

lenvatinib - In Combination with Pembrolizumab for First-Line Advanced or Metastatic Renal Cell Carcinoma

New Drug Funding Program

Pembrolizumab - In Combination with Lenvatinib for First-Line Advanced or Metastatic Renal Cell Carcinoma

Drugs Used:

lenvatinib,

pembrolizumab

... Show more tags

Quick Link(s):

Regimen Monograph

Guidelines and Advice

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Status: Current
ID: GL-END-C50-35

Dec 1969

Guidelines and Advice

An Endorsement of the 2021 Cancer Care Alberta Clinical Practice Guideline on Uveal Melanoma

Status: Current
ID: C50-CIDAP-1

Mar 2024

Regimen

AZCTGILTVENE

Intent: Curative, Palliative

Funding:

New Drug Funding Program

Azacitidine in combination with Venetoclax (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

venetoclax - Venetoclax in combination with azacitidine - Previously untreated acute myeloid leukemia

Drugs Used:

azaCITIDine,

venetoclax,

gilteritinib (Unfunded)

... Show more tags

Quick Link(s):

Regimen Monograph

Regimen

ABFM+NELA(DELAYEDINT)

Cancer Type:

Hematologic,

Leukemia - Acute Lymphoblastic (ALL)

Intent: Curative

Funding:

ODB - General Benefit

thioguanine

New Drug Funding Program

Pegaspargase (Outpatient) - Adult Acute Lymphoblastic Leukemia (ALL) Lymphoblastic Lymphoma Mixed or Biphenotypic Leukemia

New Drug Funding Program

Calaspargase Pegol (Outpatient) - Newly Diagnosed Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed_Biphenotypic Leukemia

New Drug Funding Program

Nelarabine - Newly Diagnosed T-cell Acute Lymphoblastic Leukemia

ODB - General Benefit

dexamethasone

Drugs Used: